Antidiabetic Medications and Bladder Cancer Risk in Type 2 Diabetes: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
Pooled result · Bladder cancerResult — go to the resultPooled odds ratio 0.90 95% CI 0.67–1.20Authors' conclusion
This meta-analysis suggests that antidiabetic medications, including DPP-4i, GLP-1Ras, and SGLT-2i, are not significantly associated with BC risk in T2DM patients. These findings support the long-term safety profile of these medications.
Study context
- Population
- Patients with T2D in RCTs; databases searched up to 20 June 2025
- Comparison
- Antidiabetic medications vs placebo
- Outcome
- Bladder cancer
Methodological detailsrandom-effects model, subgroup analyses by drug class
- Random-effects model
- Subgroup analyses by drug class
Pooled result
As reported in the abstract
Pooled odds ratio
0.90
95% CI 0.67–1.20
Antidiabetic medicationsvs Placebo
pooled OR 0.90 (95% CI 0.67–1.20)
Further pooled results
| Outcome | OR (95% CI) | |
|---|---|---|
| BC risk by drug class (subgroup analyses)DPP-4ivs PlaceboI2 = 0.0% | 1.12 (0.67–1.85) | |
| BC risk by drug class (subgroup analyses)GLP-1Rasvs PlaceboI2 = 0.0% | 0.72 (0.42–1.22) | |
| BC risk by drug class (subgroup analyses)SGLT-2ivs PlaceboI2 = 0.0% | 0.79 (0.50–1.24) | |
| BC risk by drug class (subgroup analyses)Pioglitazonevs Placebo | 2.37 (0.91–6.17) | |
| 0.10.31310Odds ratio (log scale) |
- Bladder cancer (BC) risk by drug class (subgroup analyses): thiazolidinediones; only one study; not statistically significant
BC risk by drug class (subgroup analyses)
- No statistically significant associations by drug class
Original publication
Antidiabetic Medications and Bladder Cancer Risk in Type 2 Diabetes: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Endocr Pract. Published 17 December 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →